← Back to patent-cliff list
Avacincaptad pegol sodium
Tier C — Watch / tradeAvacincaptad pegol sodium
Archemix Corp
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：C5
Brand：Zimura, Izervay
Indications (approved)：年龄相关性黄斑变性, 地图状萎缩
Regional status
US
Approved
2023-08-04
EU
Phase III
2015-12-15
China
Filed / under review
2026-05-07
Japan
Approved
2025-09-22
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Avacincaptad pegol sodium?
Approved indications include: 年龄相关性黄斑变性, 地图状萎缩.
When does the Avacincaptad pegol sodium patent expire?
No public expiry year is available for Avacincaptad pegol sodium yet; this page updates once verified.
How do I get a quote for Avacincaptad pegol sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27